Journal of Clinical Oncology
Articles in this Issue
Clinicogenomic determinants of early progression on first-line osimertinib in <i>EGFR</i> -mutant NSCLC.
8634 Background: With the recent approvals of the FLAURA2 and MARIPOSA regimens in EGFR...
Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study.
102 Background: In current clinical practice, ACT for stages IIB-III CRC is administered as soon as the patient is medical...
Impact of an artificial intelligence–based management model on psychological and behavioral outcomes in breast cancer patients undergoing home CDK4/6 inhibitor therapy: A multicenter randomized controlled trial.
633 Background: Patients receiving CDK4/6 inhibitors (CDK4/6i) often face significant psychological and physical challenge...
Efficacy and safety of brentuximab vedotin in relapsed or refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis.
e19065 Background: Relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) remains a major clinical challenge,...
Epidemiology and demographic patterns of mucosal lentiginous melanoma: A retrospective NCDB cohort.
e21608 Background: Mucosal lentiginous melanoma (MLM) arises from melanocytes in mucosal surfaces and is one of the rarest...
Efficacy of chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma (DLBCL): A meta-analysis.
e19005 Background: Diffuse Large B- Cell Lymphoma (DLBCL) is an aggressive lymphoma; while R-CHOP has improved outcomes, 3...
Sex-stratified outcomes, hormone receptor expression, and treatment utilization in neuroendocrine carcinoma of the breast: A population-based analysis.
e12757 Background: Neuroendocrine carcinoma of the breast (NECB) is a rare malignancy with limited contemporary population...
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
7534 Background: The definition of high-risk (HR) multiple myeloma (MM) is broad and encompasses established molecular fea...
Incidence, risk factors, and survival of secondary primary CNS tumors following hematologic malignancies: A population-based SEER study (2000-2022).
e19047 Background: Survivors of hematologic malignancies face an increased risk of secondary cancers, but the incidence an...
Real-world treatment patterns and outcomes during and after treatment with CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer.
e13052 Background: The purpose of this multicenter study was to investigate treatment patterns and real-world outcomes amo...
Synthetic data generation from breast cancer patients to enable PSM on wide and multidimensional real-world populations.
e12574 Background: In several surgical oncology domains randomized controlled trials are no longer feasible due to ethical...
Adjuvant versus no adjuvant therapy after major pathological response to neoadjuvant immunotherapy in resectable melanoma: A Swedish nationwide population-based study (NEO-MEL).
9566 Background: Randomized trials have shown that neoadjuvant PD-1–based immunotherapy improves outcomes compared with ad...
Role of circulating miR-30a-5p and miR-93-5p as liquid biopsy biomarkers for prediction of prognosis in metastatic non-small cell lung cancer.
e20529 Background: Advanced non-small cell lung cancer (NSCLC) carries a poor prognosis, and reliable non-invasive biomark...
Real-world experience with management of CRS and ICANS following CD3xCD20 bispecific antibody therapy.
e19015 Background: CD3xCD20 bispecific antibodies (BsAbs) have transformed treatment of relapsed/refractory B-cell lymphom...
Outcomes of patients with rare cancers treated with combination immune checkpoint inhibitors with and without lung and/or liver metastases (NCI/SWOG S1609).
2633 Background: Limited prior retrospective data, primarily among patients with lung cancer, liver cancer, and melanoma,...
CAR-T in the older adults: Real-world survival and toxicity in patients ≥ 75 years with relapsed/refractory multiple myeloma.
7541 Background: CAR-T cell therapy targeting BCMA has transformed the treatment landscape for relapsed/refractory multipl...
Adoption and inpatient outcomes of chimeric antigen receptor T-cell therapy in lymphomas and leukemias: A national analysis, 2017–2023.
e19104 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed or refracto...
Effect of ripretinib on the pharmacokinetics (PK) of repaglinide, a sensitive CYP2C8 probe substrate, in adult patients (pts) with advanced gastrointestinal stromal tumor (GIST).
e23511 Background: Ripretinib is a switch-control tyrosine kinase inhibitor (TKI) indicated for the treatment of adult pts...
Outcomes of hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreduction in peritoneal metastatic pancreatic adenocarcinoma: Survival benefit and impact of germline genetic mutations.
e16435 Background: Peritoneal metastasis in pancreatic ductal adenocarcinoma (PDAC) is historically associated with a dism...
Topoisomerase 1 and DNA damage: Pharmacodynamic responses and mechanism of trastuzumab deruxtecan in HER2- expressing advanced solid tumors.
3092 Background: Trastuzumab deruxtecan (T-DXd) consists of deruxtecan, a novel topoisomerase 1 (TOP1) inhibitor, covalent...
Estimation of the impact of chemotherapy-induced biological age acceleration on breast cancer survivorship using multi-scale simulation modeling.
12121 Background: Treatment of breast cancer with chemotherapy improves breast cancer survival. But chemotherapy also incr...
Cost-effective colorectal cancer screening in the United States: Comparative analyses of four molecular tests.
10525 Background: Colorectal cancer (CRC) screening in the United States is costly, largely driven by expensive colonoscop...
Age-associated differences in genomic profiles among patients with pancreatic cancer undergoing next-generation sequencing.
e16422 Background: Age is frequently used to guide treatment and clinical trial eligibility in pancreatic cancer. However,...
SBRT versus surgery for early-stage NSCLC: A propensity-matched systematic review, meta-analysis, and meta-regression.
e20037 Background: For early-stage non-small cell lung cancer (NSCLC), surgery is preferred for operable patients, while s...
Acute kidney injury in non-variceal upper gastrointestinal bleeding among patients with gastric cancer: Incidence, predictors, mortality risks, and healthcare burden.
e16020 Background: Gastric cancer patients are vulnerable to non-variceal upper gastrointestinal bleeding, a complication...